Pharmaceutical company
Seraph Pharmaceutical
Pakistan
Represent this company?Verified companies can submit portfolio corrections, documents and approved company information.Claim / verify profile →
59products
31generics
4therapeutic areas
59current prices
Portfolio intelligence
Therapeutic mix
Unclassified 49Third-generation cephalosporins 5Fluoroquinolone antibacterials 3Proton pump inhibitors 1Angiotensin II receptor blockers 1
Company portfolio
59 resultsProducts
| Brand | Generic | Strength | Form | Pack | Registration | Current price |
|---|---|---|---|---|---|---|
| Lexus | Levofloxacin | 250 mg | Tablet | 1x10's | 085288 | PKR 448.43 |
| Lizobact Lizobact | Linezolid | 100 mg/5 mL | Suspension | 120ml | 110937 | PKR 1,234.96 |
| Meraz | Omeprazole enteric coated pellets | 40 mg | Capsule | 2x7's | 085321 | PKR 448.43 |
| Meraz | Omeprazole enteric coated pellets | 20 mg | Capsule | 2x7's | 085320 | PKR 258.30 |
| Meraz | Omeprazole | 40 mg | Injection | 25's | 110933 | PKR 13,353.60 |
| Moxer | Moxifloxacin | 400 mg | Tablet | 1x5's | 085287 | PKR 852.01 |
| Oris | Risperidone | 4 mg | Tablet | 1x10's | 085306 | PKR 699.53 |
| Oris | Risperidone | 2 mg | Tablet | 2x10's | 085304 | PKR 651.73 |
| Oris | Risperidone | 3 mg | Tablet | 1x10's | 085305 | PKR 538.10 |
| Oris | Risperidone | 1 mg | Tablet | 2x10's | 085303 | PKR 400.94 |
| Sebifin | Terbinafine | 125 mg | Tablet | 1x10's | 092356 | PKR 561.43 |
| Sebifin | Terbinafine | 1% w/w | Cream | 10 gm | 093353 | PKR 272.02 |
| Sebifin | Terbinafine | 250 mg | Tablet | 1x10's | 092357 | PKR 896.84 |
| Selet | Letrozole | 2.5 mg | Tablet | 3x10's | 088455 | PKR 10,442.58 |
| Sephide | Potassium iodide | 130 mg | Tablet | 20's | 104667 | PKR 47.83 |
| Tefotaxime | Cefotaxime | 1 g | Injection | 1's | 086242 | PKR 237.37 |
| Tefotaxime | Cefotaxime | 500 mg | Injection | 1's | 086241 | PKR 163.19 |
| Tefotaxime | Cefotaxime | 250 mg | Injection | 1's | 086240 | PKR 89.01 |
| Zyban 150mg SR | Bupropion | 150 mg | Sustained-release tablet | 3x10's | 093380 | PKR 847.18 |